NCT05946993 2026-03-04
LIAM Mc
University College Cork
Phase NA Active not recruiting
Clinical Trials
37 trialsNCT05672459 2026-02-25
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04258462 2026-02-23
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
University of California, San Francisco
Phase 2 Active not recruiting
NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02950766 2026-02-03
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03091192 2026-01-23
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT05468697 2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05239533 2026-01-14
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT05820087 2025-12-22
#HOPE4KIDNEY
HistoSonics, Inc.
Phase NA Active not recruiting
NCT05030506 2025-12-18
MK-6482-010
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT06846112 2025-12-17
Randomized Clinical Trial Aimed at Comparing Unclamped Robotic Partial Nephrectomy With or Without Renorrhaphy
Regina Elena Cancer Institute
Phase NA Active not recruiting
NCT05696444 2025-11-25
Medtronic Hugoâ„¢ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
Phase NA Active not recruiting
NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT04922307 2025-11-12
RESTRICT
Vanderbilt University Medical Center
Phase NA Active not recruiting
NCT01224288 2025-11-10
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06245915 2025-09-22
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Arsenal Biosciences, Inc.
Phase 1/2 Active not recruiting
NCT05871008 2025-09-15
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
Phase NA Active not recruiting
NCT07173140 2025-09-15
RIM
University College, London
Phase NA Active not recruiting
NCT01582204 2025-08-05
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT02974738 2025-07-10
MK-6482-001
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting
NCT04000880 2025-06-12
AMPLIFY
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT04120805 2025-05-30
Random Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy
University of Chicago
Phase NA Active not recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00579514 2025-04-03
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT02306954 2025-03-10
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT04489771 2025-02-11
MK-6482-013
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03634540 2024-12-20
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT03354390 2024-12-03
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05128487 2024-11-25
A Study of NDI 1150-101 in Patients With Solid Tumors
Nimbus Therapeutics
Phase 1/2 Active not recruiting
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT03075072 2024-10-23
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
Dana-Farber Cancer Institute
Phase NA Active not recruiting
NCT05215470 2024-07-03
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Hospital das ClÃnicas de Ribeirão Preto
Phase 2 Active not recruiting
NCT02293980 2024-06-17
MK-3795-001
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting
NCT04544748 2024-03-06
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
AO GENERIUM
Phase 1 Active not recruiting